Research Collaboration

Roche aims to be the partner of choice for biotechnology companies and research institutions in Australia and worldwide

We regard external innovation as highly as our own internal discoveries and view established collaborations as a cornerstone of our research and development strategy. As a result, we have developed nearly 200 external partnerships and alliances with companies and institutes around the world.

Australian Genomic Cancer Medicine Program

Centred at the Garvan Institute, the Australian Genomic Cancer Medicine Program provides a novel approach to treating patients with rare and uncommon cancers who have exhausted all other treatment options. Through its Molecular Screening and Therapeutics (MoST) clinical trials, the Australian Genomic Cancer Medicine Program compares the genome of each patient – their entire DNA – with the genome of the patient’s tumour to discern the underlying cause of their cancer and target treatment accordingly. Individuals without a targetable driver of their cancer are offered the latest in cutting-edge immunotherapies which are showing remarkable responses in some patients. In addition, the program’s RisC trial develops surveillance protocols for individuals at genetically high risk of cancer.

Immunotherapy Centres of Research Excellence (imCORE) Network

In 2016, Roche launched imCORE, a global network of scientists and clinicians from leading cancer research institutions in cancer immunotherapy who will work together with scientists from Roche to accelerate the search for cures for people with cancer.

The research network is spread across 21 academic centres and nine countries, including Peter MacCallum Cancer Centre in Melbourne.

Monash University and Hudson Institute autoimmune diseases research collaboration

In 2016, Roche entered into an exclusive license agreement with Monash University and the Hudson Institute of Medical Research for an early-stage research collaboration, focused on proteins that stimulate anti-inflammatory pathways for the treatment of autoimmune diseases.

The collaboration aims to develop next generation treatments for autoimmune diseases, focused on proteins targeting novel molecular pathways. The partnership will enable the multi-disciplinary research team and Roche to work together to advance and translate existing and new intellectual property into novel treatments.

Investigator Initiated Studies
(IIS)

Investigator initiated clinical studies can play a key role in answering important medical and scientific questions about Roche's products and their appropriate application.

IIS are clinical studies initiated and managed by a non-pharmaceutical company researchers, like individual investigators, institutions, collaborative study groups or cooperative groups. The researcher is responsible for the legal and regulatory responsibilities of the trial sponsor for the conduct and management of the study as defined by all applicable laws and regulations.

Roche Products Pty Limited ABN 70 000 132 865 | Roche Diagnostics Australia Pty Limited ABN 29 003 001 205 | Roche Diabetes Care Australia Pty Limited ABN 69 602 140 278. This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances. This site is not intended or designed for reporting of adverse events. To report an adverse event please contact the Roche Australia Drug Safety Department immediately on Australia.drug_safety@roche.com or on +61 (0)2 9454 9444.